[1]
|
Tyler, J.A. (1985) Articular cartilage cultured with catabolin (pig interleukin 1) synthesizes a decreased number of normal proteoglycan molecules. Biochemical Journal, 227, 869-878.
|
[2]
|
Gaby, A.R. (1999) Alternative treatments for rheumatoid arthritis. Alternative Medicine Review, 4.
|
[3]
|
Pattison, D.J., Harrison, R.A. and Symmons, D.P. (2004) The role of diet in susceptibility to rheumatoid arthritis: A systematic review. The Journal of Rheumatology, 31, 1310-1319.
|
[4]
|
Edmonds, S., Winyard, P., Guo, R., Kidd, B., Merry, P., Langrish-Smith, A., Hansen, C., Ramm, S. and Blake, D.R. (1997) Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial. Annals of the Rheumatic Diseases, 56, 649-655.
doi:10.1136/ard.56.11.649
|
[5]
|
Peretz, A., Siderova, V. and Neve, J. (2001) Selenium su- pplementation in rheumatoid arthritis investigated in a double-blind, placebo-controlled trial. Scandinavian Journal of Rheumatology, 30, 208-212.
doi:10.1080/030097401316909549
|
[6]
|
Remans, P.H.J., Sont, J.K., Wagenaar, L.W., Wouter- wesseling, W., Zuijderduin, W.M., Jongma, A., Breedveld, F.C. and van Laar, J.M. (2004) Nutrient supplementation with polyunsaturated fatty acids and micronutriens in rheumatoid arthritis: Clinical and biochemical effects. European Journal of Clinical Nutrition, 58, 839-845.
doi:10.1038/sj.ejcn.1601883
|
[7]
|
Bae, S., Jung, W., Lee, E., Yu, R. and Sung, M. (2009) Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease se- verity of rheumatoid arthritis patients. Journal of the Ame- rican College of Nutrition, 28, 56-62.
|
[8]
|
Lipsky, P.E. (2000) Rheumatoid arthritis. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L. and Jameson, J.L., Eds., Harrison’s Principles of Internal Medicine, McGraw Hill, New York, 1928-1936.
|
[9]
|
Shingu, M., Nagai, Y., Isayama, T., Naono, T., Nobunaga, M. and Nagai, Y. (1993) The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clinical & Experimental Immunology, 94, 145-149.
doi:10.1111/j.1365-2249.1993.tb05992.x
|
[10]
|
Feldmann, M., Brennan, F.M. and Maini, R.N. (1996) Role of cytokines in rheumatoid arthritis. Annual Review of Immunology, 14, 397-440.
doi:10.1146/annurev.immunol.14.1.397
|
[11]
|
Gowen, M., Wood, D.D., Ihrie, E.J., Meats, J.E. and Russell, R.G. (1984) Stimulation by human interleukin 1 of cartilage breakdown and production of collagenase and proteoglycanase by human chondrocytes but not by human osteoblasts in vitro. Biochimica et Biophysica Acta, 797, 186-193. doi:10.1016/0304-4165(84)90121-1
|
[12]
|
Kevorkian, L., Young, D.A., Darrah, C., Donell, S.T., Shepstone, L., Porter, S., Brockappa Bank, S.M., Edwards, D.R., Parker, A.E. and Clark, I.M. (2004) Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis & Rheumatism, 50, 131-141.
doi:10.1002/art.11433
|
[13]
|
Martel-Pelletier, J. (1998) Pathophysiology of osteoar- thritis. Osteoarthritis and Cartilage, 6, 374-376.
doi:10.1053/joca.1998.0140
|
[14]
|
Sarban, S., Kocyigit, A., Yazar, M. and Isikan, U.E. (2005) Plasma total antioxidant capacity, lipid peroxidation, and erythrocyte antioxidant enzyme activities in patients with rheumatoid arthritis and osteoarthritis. Clinical Biochemistry, 38, 981-986.
doi:10.1016/j.clinbiochem.2005.08.003
|
[15]
|
Kamanli, A., Naziroglu, M., Aydilek, N. and Hacievliyagil, C. (2004) Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis. Cell Biochemistry and Function, 22, 53-57.
doi:10.1002/cbf.1055
|
[16]
|
Gambhir, J.K., Lali, P. and Jain, A.K. (1997) Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clinical Biochemistry, 30, 351-355.
doi:10.1016/S0009-9120(96)00007-0
|
[17]
|
Halliwell, B., Hoult, J.R. and Blake, D.R. (1988) Oxidants, inflammation, and anti-inflammatory drugs. FASEB Journal, 2, 2867-2873.
|
[18]
|
Blake, D.R., Merry, P., Unsworth, J., Kidd, B.L., Outhwaite, J.M., Ballard, R., Morris, C.J., Gray, L. and Lunec J. (1989) Hypoxid-reperfusion injury in the inflamed human joint. The Lancet, 1, 289-293.
doi:10.1016/S0140-6736(89)91305-6
|
[19]
|
Bubici, C., Papa, S., Pham, C.G., Zazzeroni, F. and Franzoso G. (2006) The NF-kappa B-mediated control of ROS and JNK signaling. Histology and Histopathology, 21, 69-80.
|
[20]
|
Siebenlist, U., Franzoso, G. and Brown, K. (1994) Structure, regulation and function of NF-kappa B. Annual Review of Cell Biology, 10, 405-455.
doi:10.1146/annurev.cb.10.110194.002201
|
[21]
|
Barnes, P.J. and Karin, M. (1997) Nuclear factor-kappa B: A pivotal transcription factor in chronic inflammatory diseases. The New England Journal of Medicine, 336, 1066-1071. doi:10.1056/NEJM199704103361506
|
[22]
|
Kumar, A., Takada, Y., Boriek, A.M. and Aggarwal, B.B. (2004) Nuclear factor-kappa B: Its role in health and disease. Journal of Molecular Medicine, 82, 434-448.
doi:10.1007/s00109-004-0555-y
|
[23]
|
Simmonds, E. and Foxwell, B.M. (2008) Signaling, inflammation and arthritis NF-kappa B and its relevance to arthritis and inflammation. Rheumatology, 47, 584-590.
|
[24]
|
Fujisawa, K., Aono, H., Hasunuma, T., Yamamoto, K., Mita, S. and Nishioka, K. (1996) Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha. Arthritis & Rheumatism, 39, 197-203. doi:10.1002/art.1780390205
|
[25]
|
Roshak, A.K., Jackson, J.R., McGough, K., Chabot-Fletcher, M., Mochan, E. and Marshall, L.A. (1996) Manipulation of distinct NF-kappa B proteins alters interleukin-1beta- induced human rheumatoid synovial fibroblast prostaglandin E2 formation. The Journal of Biological Chemistry, 271, 31496-31501. doi:10.1074/jbc.271.49.31496
|
[26]
|
Yamasaki, S., Kawakami, A., Nakashima, T., et al. (2001) Importance of NF-kappa B in rheumatoid synovial tissues: In situ NF-kappa B expression and in vitro study using cultured synovial cells. Annals of the Rheumatic Diseases, 60, 678-84. doi:10.1136/ard.60.7.678
|
[27]
|
Carlsen, H., Moskaug, J.O., Fromm, S.H. and Blomhoff, R. (2002) In vivo imaging of NF-kappa B activity. The Journal of Immunology, 168, 1441-1446.
|
[28]
|
Sioud, M., Mellbye, O. and Forre, O. (1998) Analysis of the NF-kappa B p65 subunit, Fas antigen, Fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA. Clinical and Experimental Rheumatology, 16, 125-134.
|
[29]
|
Marok, R., Winyard, P.G., Coumbe, A. et al. (1996) Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis & Rheumatism, 39, 583-591. doi:10.1002/art.1780390407
|
[30]
|
Handel, M.L., McMorrow, L.B. and Gravallese, E.M. (1995) Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis & Rheumatism, 38, 1762-1770. doi:10.1002/art.1780381209
|
[31]
|
Benito, M.J., Murphy, E., Murphy, E.P., van den Berg, W.B., FitzGerald, O. and Bresnihan, B. (2004) Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis & Rheumatism, 50, 1781-1787.
doi:10.1002/art.20260
|
[32]
|
Danning, C.L., Illei, G.G., Hitchon, C., Greer, M.R., Boumpas, D.T. and McInnes, I.B. (2000) Macrophage- derived cytokine and nuclear factor kappa B p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis & Rheumatism. 43, 1244-1256.
doi:10.1002/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2
|
[33]
|
Tsao, P.W., Suzuki, T., Totsuka, R., et al. (1997) The effect of dexamethasone on the expression of activated NF-kappa B in adjuvant arthritis. Clinical Immunology and Immunopathology, 83, 173-178.
doi:10.1006/clin.1997.4333
|
[34]
|
Han, Z., Boyle, D.L., Manning, A.M. and Firestein, G.S. (1998) AP-1 and NF-kappa B regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity, 28, 197-208. doi:10.3109/08916939808995367
|
[35]
|
Wehling, N., Palmer, G.D., Pilapil, C., Liu, F., Wells, J.W., Müller, P.E., Evans, C.H. and Porter, R.M. (2009) Interleukin-1beta and tumor necrosis factor alpha inhibit chondrogenesis by human mesenchymal stem cells through NF-kappa B-dependent pathways. Arthritis & Rheuma- tism, 60, 801-812. doi:10.1002/art.24352
|
[36]
|
Li, X.L. and Makarov, S.S. (2006) An essential role of NF-κB in the “tumor-like” phenotype of arthritic synoviocytes. Proceedings of the National Academy of Sciences, 103, 17432-17437. doi:10.1073/pnas.0607939103
|
[37]
|
Yamasaki, S., Nakashima, T., Kawakami, A., Miyashita, T., Tanaka, F., Ida, H., Migita, K., Origuchi, T. and Eguchi, K. (2004) Cytokines regulate fibroblast-like synovial cell differentiation to adipocyte-like cells. Rheumatology, 43, 448-452.
|
[38]
|
Zvaifler, N.J., Tsai, V., Alsalameh, S., von Kempis, J., Firestein, G.S. and Lotz, M. (1997) NF-KB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. American Journal of Pathology, 150, 1125-1138.
doi:10.1073/pnas.95.23.13859
|
[39]
|
Miagkov, A.V., Kovalenko, D.V., Borwn, C.E., Didsbury, J.R., Cogswell, J.P., Stimpson, S.A., Baldin, A.S. and Makarov SS. (1998) NF-KB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proceedings of the National Academy of Sciences of the USA, 95, 13859-13864.
|
[40]
|
Bendich, A. and Langseth, L. (1995) The health effects of vitamin C supplementation: A review. Journal of the American College of Nutrition, 14, 124.
|
[41]
|
Cathcart, R. F. (1984) Vitamin C in the treatment of acquired immune deficiency syndrome (AIDS). Medical Hypotheses, 14, 423. doi:10.1016/0306-9877(84)90149-X
|
[42]
|
Mikirova, N.A., Ichim, T.E. and Riordan, N.H. (2008) Anti-angiogenic effect of high doses of ascorbic acid. Journal of Translational Medicine, 6.
|
[43]
|
Duconge, J., Miranda-Massari, J.R., Gonzalez, M.J., Jackson, J.A., Warnock, W. and Riordan, N.H. (2008) Pharmacokinetics of vitamin C: Insights into the oral and intravenous administration of ascorbate. Puerto Rico Health Sciences Journal, 27, 7-19.
|
[44]
|
Duconge, J., Miranda-Massari, J.R., González, M.J., Taylor, P.R., Riordan, H.D., Riordan, N.H., Casciari, J.J. and Alliston, K. (2007) Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. The Annals of Pharmacotherary, 41, 1082-1083.
doi:10.1345/aph.1H654
|
[45]
|
Riordan, H.D., Casciari, J.J., González, M.J., Riordan, N.H., Miranda-Massari, J.R., Taylor, P. and Jackson, J.A. (2005) A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. Puerto Rico Health Sciences Journal, 24, 269-276.
|
[46]
|
Riordan HD et al (1990) Case study: High-dose intravenous Vitamin C in the treatment of a patient with adenocarcinoma of the kidney. Journal of Orthomolecular Medicine, 13.
|
[47]
|
Ichim, T.E., Minev, B., Braciak, T., Luna, B., Hunninghake, R., Mikirova, N.A., Jackson, J.A., Gonzalez, M.J., Miranda-Massari, J.R., Alexandrescu, D.T., Dasanu, C., Bogin, V., Ancans, J., Stevens R.B., Markosian, B., Koropatnick, J., Chen, C.-S., and Riordan, N.H. (2011) Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? Journal of Translational Medicine, 9, 25. doi:10.1186/1479-5876-9-25
|
[48]
|
Mikirova, N., Casciari, J., Rogers, A. and Taylor, P. (2012) Effect of high-dose intravenous vitamin C on inflammation in cancer patients. Journal of translational medicine, 10, 189. doi:10.1186/1479-5876-10-189
|
[49]
|
Ford, E.S., Liu, S., Mannino, D.M., Giles, W.H. and Smith, S.J. (2003) C-reactive protein concentration and concentrations of blood vitamins, carotenoids, and selenium among United States adults. European Journal of Clinical Nutrition, 57, 1157-1163.
doi:10.1038/sj.ejcn.1601667
|
[50]
|
H?rtel, C., Strunk, T., Bucsky, P. and Schultz, C. (2004) Effects of vitamin C on intracytoplasmic cytokine production in human whole blood monocytes and lymphocytes. Cytokine, 27, 101-106.
doi:10.1016/j.cyto.2004.02.004
|
[51]
|
Caecamo, J.M., Borquez-Ojeda, O. and Golde, D.W. (2002) Vitamin C inhibites macrophage-colony-stimulating fac- tor-induced signaling pathways. Blood, 99, 3205-3212.
doi:10.1182/blood.V99.9.3205
|
[52]
|
Bowie, A.G. and O’Neill, L.A.J. (2000) Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase1. The Journal of Immunology, 165, 7180-7188.
|
[53]
|
Munoz, E., Blazquez, M.V., Ortiz, C., Gomez-Diaz, C. and Navas, P. (1997) Role of ascorbate in the activation of NF-kappa B by tumor necrosis factor-a in T-cells. Biochemical Journal, 325, 23.
|
[54]
|
Harakeh, S., Jariwalla. R. J. (1997). NF-kappa B-inde- pendent suppression of HIV expression by ascorbic acid. AIDS Research and Human Retroviruses, 13, 235.
doi:10.1089/aid.1997.13.235
|
[55]
|
Bowie, A.G., Carcamo, J.M., Pedraza, A., Borquez-Qjeda, O. and Golde, D.W. (2002) Vitamin C suppresses TNFa- induced NFκB activation by inhibiting IκBα phosphorilation. Biochemistry, 41, 12995-13002.
doi:10.1021/bi0263210
|
[56]
|
Halliwell, B. and Gutteridge, J.M. (1999) Free Radicals in Biology and Medicine, Oxford University Press, New York.
|
[57]
|
Calder, P.C., Albers, R., Antoine, J.M., et al. (2009) Inflammatory disease processes and interactions with nutrition. British Journal of Nutrition, 101, S1-S45.
|
[58]
|
Boyera, N., Galey, I. and Bernard, B.A. (1998) Effect of vitamin C and its derivatives on collagen synthesis and cross-linking by normal human fibroblasts. International Journal of Cosmetic Science, 20, 151-158.
|
[59]
|
Franceschi, R.T., Iyer, B.S. and Cui, Y.L. (1994) Effects of ascorbic acid on collagen matrix formation and osteoblast differentiation in murine MC3T3-E1 cells. Journal of Bone and Mineral Research, 9, 843-854.
|
[60]
|
Abrams E, Sandsont J. (1964) Effect of ascorbic acid on rheumatoid synovial fluid. Annals of the Rheumatic Diseases, 23, 295.
doi:10.1161/01.CIR.0000125690.80303.A8
|
[61]
|
Riordan, H.D., Casciari, J.J., González, M.J., Riordan, N.H., Miranda-Massari, J.R., Taylor, P. and Jackson, J.A. (2005) A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. Puerto Rico Health Sciences Journal, 24, 269-276.
|
[62]
|
Ridker, P.M. and Cook, N. (2004) Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation, 109, 1955-1959.
|
[63]
|
Goodson, N.J., Symmons, D.P., Scott, D.G., Bunn, D., Lunt, M. and Silman, A.J. (2005) Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: A ten-year follow up study of a primary care-based inception cohort. Arthritis & Rheumatism, 52, 2293-2299.
doi:10.1002/art.21204
|